Why SEER matters now
Seer, Inc. (SEER) is a US stock in Healthcare. The latest InvestLog snapshot shows $2.17 with -1.81% on the session and $119.3M in market capitalization; recent performance reads 1-month +3.57% and YTD -4.92%.
The latest financial table shown here is Q1 2026, with revenue of $2.8M, net income of $-16.8M, and EPS of $-0.30. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -52.1%.
The latest indexable market news headline is "Seer and Nanyang Technological University to Present Early Findings from Landmark PRECISE-SG100K Proteomics Study at HUPO 2026" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $4.00; recent insider activity includes Horn David R. filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.40
P/S
6.36
EV/EBITDA
-1.11
DCF Value
$-11.08
FCF Yield
-52.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
48.3%
Operating Margin
-496.4%
Net Margin
-468.7%
ROE
-26.6%
ROA
-25.9%
ROIC
-28.2%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $2.8M | $-16.8M | $-0.30 |
| Q4 2025 | $4.1M | $-16.0M | $-0.29 |
| FY 2025 | $16.1M | $-73.6M | $-1.28 |
| Q3 2025 | $4.1M | $-18.2M | $-0.32 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$4.00
Target (Median)
$4.00
Target Range
$4.00 - $4.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.59
Seer, Inc. is a life sciences firm specializing in developing and commercializing advanced technologies designed to unravel the complexities of the proteome. At the core of its offerings is the Proteograph Product Suite, an integrated platform comprising specialized consumables, automated instrumentation, and sophisticated software. This comprehensive solution empowers researchers to conduct advanced proteomic studies across various applications, including therapeutic and diagnostic investigations, as well as clinical trials. The company markets its products exclusively for research applications, serving academic institutions, diverse life sciences and research laboratories, and biopharmaceutical and biotechnology enterprises. Notably, these offerings are intended for non-diagnostic and non-clinical purposes. Seer has established collaborative agreements with entities such as Discovery Life Sciences, LLC, and the Salk Institute for Biological Studies. Originally incorporated in 2017 as Seer Biosciences, Inc., the company adopted its current name, Seer, Inc., in July 2018. Its headquarters are situated in Redwood City, California.